Pharma firm Abzena to list

ABZENA, the biopharmaceutical research specialist, yesterday announced its intention to float on London’s junior stock market to raise an undisclosed sum.

Abzena, which has £5.8m of annual revenues, helps develop therapeutic proteins and antibodies.

The group’s major institutional investors include Invesco Perpetual, the former home of Neil Woodford, and Imperial Innovations, a specialist in commercialising university research that owns 26.2 per cent.

The sale will include new and existing shares, to be listed on the Alternative Investment Market next month.